News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Endocyte, Inc. (ECYT) Provides Update On CHMP Review Of Pending EU Conditional Marketing Authorization Applications For Vintafolide And Etarfolatide


1/24/2014 9:21:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WEST LAFAYETTE, Ind., Jan. 24, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today provided an update regarding the review of the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) on the pending EU conditional marketing authorization applications for vintafolide, etarfolatide and intravenous (IV) folic acid.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES